Search
Romlusevimab
go.drugbank.com/drugs/DB16494InvestigationalRomlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.
INM005
go.drugbank.com/drugs/DB16499InvestigationalIt was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984). … Additionally, a retrospective cohort study investigated the effectiveness and safety of specific hyperimmune equine serum for severe hospitalized COVID-19 patients (NCT04954235)
KAND567
go.drugbank.com/drugs/DB16511InvestigationalKAND567, a small molecule, blocks the fractaline (CX3CL1) receptor, which mediates the immune system response to inflammation[L32908]. … Because COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently being tested as a treatment for those with the illness[L32908].
Zofin
go.drugbank.com/drugs/DB16519InvestigationalZofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the
KB109
go.drugbank.com/drugs/DB16531ExperimentalKB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.
Zirconium dioxide
go.drugbank.com/drugs/DB16552InvestigationalCategories: Compounds used in a research, industrial, or household settingVitis vinifera seed
go.drugbank.com/drugs/DB16606InvestigationalCategories: Compounds used in a research, industrial, or household settingInfluenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16646ApprovedSynonyms: Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated), Haemagglutinin-strain A (H5N1)Categories: Inactivated Influenza A Virus VaccineEpcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigational[L46516] It is administered subcutaneously and is currently being evaluated as a monotherapy and in combination for the treatment of a variety of hematologic malignancies. … Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).